LLY•benzinga•May 21, 2024 at 02:53 PM

Novo Nordisk CEO, On Lilly's Diabetes Drug Approval In China, Says It's One More Market Where There Will Be Two Critical Contenders Competing; Supplying All We Can, There Is No Drug Shortage Of Our Type 2 Diabetes Drug Ozempic In The U.S. Market; On Compo

No summary available.

Read the full article from the original source for complete details and context.

Article published on May 21, 2024 by benzinga